Foresite Capital has had a busy beginning to their 2017 year. The medical research growth equity firm has been bringing on high profile, big name talent to their team. New addition Jim Tananbaum, M.D, was named to the Forbe’s Midas List of Top Tech Investors for an incredible third straight time. On the heels of his successful month the company decided to add another venture partner to the team, Dr. Molly He. News of Dr. He’s addition to the team was welcomed and immediately receptive from high ranking members of Foresite Capital.
The first person to welcome Dr. He to the team was Dr. Jim Tananbaum himself. Dr. Tananbaum spoke in a statement regarding Dr. He where he regarded her as one of the most respected of scientific researchers in the field of next generation sequencing. Dr. Tananbaum regaled her experience in the field of genomics as well as drug development and considered her also a remarkable leader with an extensive track record as both a leader and a team member. He finished off his statement by calling her ‘an invaluable resource to Foresite’ as they ‘continue to expand and diversify our portfolio of transformational companies.’
According to Fierce Biotech, Dr. Tananbaum’s words are more than just fluff to welcome a new employee. Dr. Tananbaum himself established Foresite Capital and he has a total of 25 years’ worth of leadership within the industry. Tananbaum’s been an active investor in the healthcare field while focusing on the different ways you can build and develop franchise healthcare businesses. Dr. Jim Tananbaum also helped to co-found GelTex Pharmaceuticals which managed to bring two different drugs to the market before being bought out for a jaw dropping $1.6 billion.
Of course, Dr. He would not be invited to the team without her own skills evidenced and on display. Dr. He previously worked as the senior director of scientific research over at Illumina where she served the company for years. Before Illumina Dr. He had spent ten years in the pharmaceutical industry as well as in a leadership role over at Pacific Biosciences. Needless to say, Dr. He will be welcomed with open arms at Foresite Capital. More details can be found on LinkedIn.